loader image
Friday, November 21, 2025
76 F
McAllen
- Advertisement -

UT Health RGV now offering pre-registration for children ages 12-15

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

By News and Internal Communications

RIO GRANDE VALLEY, TEXAS – With news that FDA approval of the COVID-19 vaccine for ages 12-15 is now imminent, UT Health RGV is anticipating they will soon be able to administer the vaccine to this age group.

In preparation of the announcement, UT Health RGV is encouraging parents or legal guardians to pre-register their children at uthealthrgv.org/minor-registration, so that they can be first in line to receive the vaccine once it is approved in the coming days.

- Advertisement -

Please keep in mind that all minors must be accompanied by a parent or legal guardian.

To learn more about UT Health RGV’s COVID-19 vaccine efforts, visit https://uthealthrgv.org/health-care-news/coronavirus/vaccine/.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Paxton Secures $41.5M from Pfizer & Tris Pharma for Providing Adulterated Drugs to Children

Attorney General Ken Paxton has secured a $41.5 million settlement with Pfizer and Tris Pharma for allegedly providing adulterated pharmaceutical drugs to Texas children in violation of the Texas Health Care Program Fraud Prevention Act (“THFPA”).    

STHS’ South Texas Healthy Living Episode on Diabetes Awareness, Nov. 30th

The United States is experiencing a national health crisis as the incidence of diabetes continues to climb across the country.

DHR Health Encourages Early Detection with $99 Lung Cancer Screening Special Thru Dec. 31st

Lung cancer remains the leading cause of cancer death in the United States, accounting for about one in five cancer deaths nationwide. According to the American Cancer Society, an estimated 226,650 new cases of lung cancer will be diagnosed in 2025, and 124,730 people are expected to die from the disease. Each year, lung cancer claims more lives than colon, breast, and prostate cancers combined.

Aesculap Implant Systems Settles for $38.5M, Enters Non-Prosecution Deal

Medical device company Aesculap Implant Systems LLC (Aesculap), based in Center Valley, Pennsylvania, has agreed to pay $38.5 million to resolve allegations under the False Claims Act that the company sold knee replacement devices that it knew would fail prematurely at a higher than acceptable rate, resulting in false claims to Medicare and Medicaid.
- Advertisement -
×